Sign inJoin waitlistJoin the waitlist

Fahrettin Covut

Physician · UnityPoint Health - Trinity

Credentials: · · · · · · ·

History

UnityPoint Health - Trinity
2025–Present

Hematology and Medical Oncology
Washington University/B-JH/SLCH Consortium
2020–2023
Cleveland Clinic Foundation
2017–2020
University of Istanbul, Istanbul, Turkey
2011–2015

Research

Tocilizumab for treatment of patients with severe COVID-19: A retrospective cohort study
EClinicalMedicine · 2020 · 120 citations
Prevalence and Predictors of Gastrointestinal Dysmotility in Patients with Hypermobile Ehlers-Danlos Syndrome: A Tertiary Care Center Experience
Cureus · 2020 · 45 citations
Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study
British Journal of Haematology · 2021 · First of 12 authors · 35 citations

Tariq Kewan
10 papers
Ehsan Malek
9 papers
Hamed Daw
9 papers
Marcos de Lima
9 papers
Mohammad Alomari
9 papers · 9 as a resident
Abdo Haddad
8 papers
Pravallika Chadalavada
8 papers · 8 as a fellow
Brenda Cooper
6 papers
Laith Al Momani
5 papers · 5 as a fellow
Paolo Caimi
5 papers
Hillard Lazarus
4 papers
Leland Metheny
4 papers

Clinical trials

Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical Cancer
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2030
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037
Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
Site PI · Recruiting · Phase 3
National Cancer Institute (NCI)
2025–2029
Testing the Addition of the Anti-Cancer Drug Tivozanib to Immunotherapy (Pembrolizumab) After Surgery to Remove All Known Sites of Kidney Cancer
Site PI · Recruiting · Phase 3
Alliance for Clinical Trials in Oncology
2025–2037